(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
In these U.S. groups, deaths now exceed births. What’s happening? - 2A Lone Wolf Outsmarted Hunters in the Black Forest and Then Vanished
- 3Renewables cover over 50% of German electricity consumption in Q1
- 4UK to hold fresh pork, other affected Spanish products at border amid African swine fever outbreak
- 5Three arrested in Paris after attempted bomb attack outside Bank of America
- Why most Jewish Israelis back the death penalty for terrorists
- Thousands of Walgreens nasal spray bottles recalled. See which ones.
- 3 Must-Change Settings for iPhone Clients: Safeguard Yourself !
- CDC pauses dozens of types of lab testing during evaluation and in wake of downsizing
- Picking the Right Doctor prescribed Medication Inclusion in Senior Protection.
- Amy Poehler's podcast is a hit. It's also a Trojan horse for talking about women and aging.
- Popular Home Rug Series For You
- Going on a bad date is a drag. Worse? Ending up as a cautionary tale on TikTok.
- From invasive species tracking to water security – what’s lost with federal funding cuts at US Climate Adaptation Science Centers
